Vimarsana
Biggest News Aggregation in the World

Page 50 - Loss Attributable News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Loss Attributable. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Loss Attributable Today - Breaking & Trending Today

Harbor Custom Development, Inc. Reports Record Revenues In 2022 First Quarter Financial Results - Vimarsana News

Harbor Custom Development, Inc. Reports Record Revenues In 2022 First Quarter Financial Results

12.05.2022 - Continued Strength in Buyer Demand Drives Year-over-Year Sales Increase of 106.0%TACOMA, Wash., May 12, 2022 (GLOBE NEWSWIRE) - Harbor Custom Development, Inc. (“Harbor,” “Harbor Custom Homes,” or the “Company”), (NASDAQ: HCDI; HCDIP; HCDIW, ...

Nuvve Provides First Quarter 2022 Financial Update - Vimarsana News

Nuvve Provides First Quarter 2022 Financial Update

/PRNewswire/ -- Nuvve Holding Corp. (Nuvve) (Nasdaq: NVVE), a global cleantech company electrifying the planet at the intersection of energy and transportation...

Nuvve Provides First Quarter 2022 Financial Update - Vimarsana News

Nuvve Provides First Quarter 2022 Financial Update

/PRNewswire/ -- Nuvve Holding Corp. (Nuvve) (Nasdaq: NVVE), a global cleantech company electrifying the planet at the intersection of energy and transportation...

F-star Therapeutics, Inc.: F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update - Vimarsana News

F-star Therapeutics, Inc.: F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Four Clinical Readouts Anticipated Throughout 2022 Mechanistic Data on FS118 Demonstrating Shedding Mechanism and LAG-3 Reduction Presented at the 2022 American Association for Cancer Research (AACR)

F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update - Vimarsana News

F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer, today announced first quarter 2022 financial results and provided a corporate update ...